IMR-1
CAS No. 310456-65-6
IMR-1( IMR-1 | IMR 1 | IMR1. Inhibitor of Mastermind Recruitment-1 )
Catalog No. M17472 CAS No. 310456-65-6
IMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μMol/L.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 27 | In Stock |
|
5MG | 43 | In Stock |
|
10MG | 73 | In Stock |
|
25MG | 155 | In Stock |
|
50MG | 281 | In Stock |
|
100MG | 462 | In Stock |
|
500MG | 1035 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIMR-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionIMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μMol/L.
-
DescriptionIMR-1 is a Mastermind Recruitment inhibitor. IMR-1 disrupted the recruitment of Mastermind-like 1 to the Notch transcriptional activation complex on chromatin, thereby attenuating Notch target gene transcription. IMR-1 inhibited the growth of Notch-dependent cell lines and significantly abrogated the growth of patient-derived tumor xenografts.
-
In Vitro——
-
In VivoAnimal Model:Nude mouses with adenocarcinoma xenograft.Dosage:15mg/kg Administration:I.p.; for 28 days Result:Blocks tumor establishment.
-
SynonymsIMR-1 | IMR 1 | IMR1. Inhibitor of Mastermind Recruitment-1
-
PathwayOthers
-
TargetOther Targets
-
RecptorNotch
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number310456-65-6
-
Formula Weight353.41
-
Molecular FormulaC15H15NO5S2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL 282.96 mM; H2O : < 0.1 mg/mL
-
SMILESC(=O)(COc1c(cc(cc1)/C=C/1\SC(=S)NC1=O)OC)OCC
-
Chemical Name(E)-Ethyl 2-(2-methoxy-4-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)phenoxy)acetate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Astudillo L, et al. Cancer Res. 2016, 76(12):3593-603.
molnova catalog
related products
-
Gamma-Methylleucine
Gamma-Methylleucine is an auxiliary for copper-catalyzed asymmetric Michael reactions.
-
Lumiracoxib
Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1. Phase 4.
-
1,4-Anthraquinone
1,4-Anthraquinone is an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation.